Related references
Note: Only part of the references are listed.Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program
Heinz Wiendl et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
Helmut Butzkueven et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Outcomes of natalizumab treatment within 3years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
Jai Perumal et al.
BMC NEUROLOGY (2019)
Progressive multiple sclerosis, cognitive function, and quality of life
Helene Hojsgaard Chow et al.
BRAIN AND BEHAVIOR (2018)
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
Maria Trojano et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?
Laura Barin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study
Mehrdokht Mazdeh et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review
Magaly Lecat et al.
EUROPEAN NEUROLOGY (2017)
Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study
Vincent Planche et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Long- term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis
John F. Foley et al.
PATIENT PREFERENCE AND ADHERENCE (2017)
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
Peter Joseph Jongen
CNS DRUGS (2017)
Improvement in fatigue during natalizumab treatment is linked to improvement in depression and day-time sleepiness
Iris-Katharina Penner et al.
FRONTIERS IN NEUROLOGY (2015)
Estimating a minimal clinically important difference for the EuroQol 5-dimension health status index in persons with multiple sclerosis
Christine G. Kohn et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
Helmut Butzkueven et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis
Laura C. Schairer et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Health-related quality of life as an independent predictor of long-term disability for patients with relapsingremitting multiple sclerosis
K. Baumstarck et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Preference-based Health status in a German outpatient cohort with multiple sclerosis
Jens Peter Reese et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2013)
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting
Anders Svenningsson et al.
PLOS ONE (2013)
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
Judith J. Stephenson et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2012)
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis
J. Theodore Phillips et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and Treatment
Tiffany J. Braley et al.
SLEEP (2010)
Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis
Howard L. Zwibel
ADVANCES IN THERAPY (2009)
Validation of the multiple sclerosis international quality of life questionnaire
M. C. Simeoni et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Health-related quality of life in multiple sclerosis: Effects of Natalizumab
Richard A. Rudick et al.
ANNALS OF NEUROLOGY (2007)
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
L. J. Balcer et al.
NEUROLOGY (2007)
Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing
AJ Mitchell et al.
LANCET NEUROLOGY (2005)